Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Should You Buy?

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) gapped up prior to trading on Monday . The stock had previously closed at $1.49, but opened at $1.7150. Autolus Therapeutics shares last traded at $2.0150, with a volume of 3,178,453 shares trading hands.

Autolus Therapeutics News Summary

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Autolus reported preliminary second-quarter 2026 AUCATZYL net product revenue of approximately $45 million and raised its full-year 2026 sales guidance to $140 million-$150 million from $120 million-$135 million. The new range is also above the roughly $128.1 million consensus estimate, signaling better-than-expected commercial momentum. Autolus preliminary second-quarter revenue and credit facility announcement
• Positive Sentiment: The company also reported an approximately 35% year-to-date gross margin and secured a five-year, interest-only credit facility of up to $250 million, with $75 million funded at closing. The financing improves near-term liquidity to support manufacturing and commercialization, though it adds debt obligations.
• Positive Sentiment: HC Wainwright reiterated its Buy rating and $10 price target. The analyst raised estimated losses for the second and third quarters of 2026 to $0.22 and $0.21 per share, respectively, from $0.31 and $0.27, and lifted the full-year 2026 estimate to a $0.88 loss from $1.08. HC Wainwright reiterates Buy rating for Autolus Therapeutics
• Neutral Sentiment: Autolus will release complete second-quarter 2026 results and operational updates before the U.S. market opens on August 11. Investors will look for confirmation of the preliminary revenue, gross margin, AUCATZYL demand and cash outlook. Autolus second-quarter 2026 earnings release date
• Negative Sentiment: Despite the improved 2026 outlook, HC Wainwright reduced its EPS forecasts for 2027 through 2030, including cuts to a $0.74 loss for 2027, an $0.83 loss for 2028 and a $0.69 loss for 2029. These revisions suggest profitability may take longer to achieve and could limit the stock’s upside.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Weiss Ratings cut Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Wall Street Zen upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Autolus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $8.75.

Autolus Therapeutics Stock Performance

The company has a market capitalization of $519.01 million, a PE ratio of -1.79 and a beta of 2.07. The company has a 50 day moving average price of $1.58 and a 200 day moving average price of $1.53.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. The business had revenue of $26.22 million during the quarter, compared to analyst estimates of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. On average, equities analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.95 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AUTL. GAMMA Investing LLC grew its position in shares of Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after acquiring an additional 8,309 shares in the last quarter. Independent Advisor Alliance acquired a new stake in shares of Autolus Therapeutics during the 4th quarter valued at approximately $28,000. Marex Group plc bought a new position in Autolus Therapeutics during the second quarter worth $28,000. Waverly Advisors LLC bought a new position in Autolus Therapeutics during the first quarter worth $37,000. Finally, SmartHarvest Portfolios LLC acquired a new position in Autolus Therapeutics in the fourth quarter worth $43,000. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.